Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD138 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Shunde Hospital, Southern Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD138 CAR-T cells are an autologous cell therapy being investigated for the treatment of relapsed or refractory multiple myeloma. These T cells are genetically engineered to express a chimeric antigen receptor (CAR) that targets CD138 (Syndecan-1), a protein highly expressed on the surface of malignant plasma cells. By binding to CD138, the CAR-T cells are directed to recognize and eliminate myeloma cells. In clinical studies conducted by Shunde Hospital of Southern Medical University, these cells have been evaluated both as a monotherapy and in combination with anti-BCMA CAR-T cells to overcome antigen escape and improve therapeutic outcomes in patients with advanced plasma cell dyscrasias.
- Other names
- CD138-directed CAR-T cellsCD-138-directed CAR-T cellsCD 138-directed CAR-T cellsanti-CD138 chimeric antigen receptor T cellsanti-CD-138 chimeric antigen receptor T cellsanti-CD 138 chimeric antigen receptor T cells
02
Targets
SDC1 (Syndecan-1)
Beyond the preview
Go deeper on anti-CD138 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD138 CAR-T cells.